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Abstract 
Background:  
In 2004, the Infectious Diseases Society of America (IDSA) published monitoring guidelines for 
outpatient parenteral antimicrobial therapy (OPAT), but no assessment of their utilization has 
been reported. We evaluated adherence to these recommendations by physicians at infusion 
centers and then piloted a program of supervision of monitoring by pharmacists.  
 
Methods: 
Phase I: We performed a retrospective case-control study of patients who received OPAT over 
one year at two hospital infusion centers. Controls were patients treated by an infectious diseases 
(ID) physician, and cases were those without an ID physician. Patients were excluded if they 
received fewer than 3 days of OPAT. Clinical pharmacy monitoring services were then 
implemented for patients on OPAT prescribed by non-ID physicians at one hospital’s infusion 
unit. Two outcomes were measured: adherence to guidelines on monitoring, and attainment of 
goal vancomycin and aminoglycoside serum concentrations when appropriate. The results for 
non-ID physicians were compared to both ID physicians and subsequently a pharmacist.  
 
Results: 
Ninety nine patients were included in the retrospective study. Compared with patients who had 
ID physician supervision, the non-ID physicians who prescribed OPAT for 39 patients had lower 
adherence to monitoring recommendations (35.9% vs.68.3%, p=0.003). No difference could be 
detected in achievement of goal vancomycin and aminoglycoside serum concentrations for the 
14 cases and 19 controls requiring therapeutic drug monitoring (57.1% vs. 68.4% respectively, 
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p=0.765). Seven patients were enrolled in the study after pharmacy monitoring was 
implemented. Adherence to monitoring recommendations for these patients was significantly 
improved compared to the prior patients that lacked ID physician supervision (35.9% vs. 100%, 
p=0.0065).   
 
Conclusions: 
Non-ID physicians are less likely to monitor OPAT according to the IDSA guidelines than ID 
physicians; however, pharmacist oversight improves adherence to recommendations. Further 
studies of monitoring of OPAT by pharmacists should investigate the impact of pharmacist 
involvement on prevention of adverse events and hospital readmissions.   
 
Key words: 
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Background 
Patients with moderate to severe infections may require intravenous (IV) antibiotics for their 
entire course of therapy. However, many of these patients may be stable enough to receive 
treatment as an outpatient. Outpatient parenteral antimicrobial therapy (OPAT) is defined as 
providing IV, intramuscular or subcutaneous administration of antibiotics, antifungals, and 
antivirals to patients on separate days outside of a hospital setting.1 One of the goals of OPAT is 
to deliver high-quality health care while optimizing resource use and reducing costs without 
compromising clinical outcomes. With the availability of antimicrobials with long half-lives that 
allow for once or twice daily dosing, OPAT is feasible for a variety of infectious diseases. 
Examples of infections that have been effectively treated with OPAT include skin and soft tissue 
infections, osteomyelitis, bacteremia, endocarditis, and complicated urinary tract infections.2-6 
 
Mounting evidence supports the use of OPAT. The documented benefits include cost savings and 
patient convenience.1,2 Using OPAT allows for additional inpatient hospital beds and healthcare 
resources to be available for other more acute patients and it can lead to a reduction in the risk of 
healthcare-related infections.3,8 Infection acquired during a hospitalization results in an estimated 
cost of $2,100 and a total cumulative cost of greater than $2 billion annually.8 An article by 
Nguyen showed that the implementation of an OPAT service for a hospitalist service at his 619-
bed acute-care medical center translated to an estimated mean savings of over $7,000 per 
patient.3 In addition to cost avoidance, OPAT can allow patients to return home, improving their 
quality of life and satisfaction with care.1 Due to the cost savings and other benefits noted, OPAT 
services are becoming more attractive to healthcare systems, especially in light of increasing 
financial and regulatory pressures.3  
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OPAT can be provided in various settings, including physician’s offices, infusion centers, long-
term care facilities, dialysis centers and even the patient’s home with visiting nurse or self-
administration of the drug. In one recent U.S. study, 65% of inpatients discharged on OPAT 
received infusions at home, 15% at long term care facilities, 11% at infusion centers and 9% at 
other facilities such as dialysis clinics or physicians’ offices.7 The patient’s condition and source 
of payment often direct where patients on OPAT may be discharged.    
 
Several key features make an OPAT program successful and efficient (e.g. the OPAT bundle 
concept as suggested by Muldoon et al.9). These include: careful patient selection; an organized 
OPAT team consisting of an ID physician, infusion pharmacist, nurses, case management, billing 
staff, social worker and primary care or referring physicians available to participate in care; 
effective communication between the OPAT team, patient and other healthcare professionals; 
optimal patient surveillance and monitoring; and a program in place to monitor outcomes.4,7,9 
The American Society of Health-System Pharmacists has published guidelines highlighting the 
pharmacist’s contribution to this team approach, including monitoring antimicrobial therapy .10,11   
 
Unlike the inpatient setting where a patient is closely observed, patients on OPAT may 
experience much less monitoring.1 At least 25% of patients receiving OPAT will develop 
adverse reactions however, and up to 10% of patients on OPAT will discontinue therapy due to 
an adverse event.1,4 A 1999 report of 269 patients who received OPAT at home during a 2 year 
period, found that 16% developed leukopenia, 7% neutropenia, 4% thrombocytopenia and 8% 
nephrotoxicity. Overall, 8% of patients required re-hospitalization. The authors concluded that 
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monitoring of patients receiving OPAT is important to prevent complications and hospital 
readmissions.12  
 
In 2004 the Infectious Diseases Society of America (IDSA) updated their 1997 guidelines for 
OPAT, including recommendations for monitoring. These practice guidelines serve as a 
benchmark for clinical monitoring and quality assurance.1,4 With the implementation of these 
guidelines plus vigilant risk assessment and management, the hazards associated with OPAT can 
be minimized.1 The guidelines are voluntary and no reports of rates of adherence have been 
published. Therefore, we evaluated adherence to the laboratory monitoring recommendations, 
including attainment of goal serum drug concentrations, by physicians at infusion centers and 
then pilot clinical pharmacy monitoring services in an existing OPAT program.  
 
Methods 
Phase 1 
This was a two phase study approved by the local institutional review board. The first phase was 
a retrospective case-control study. Controls were defined as patients treated by an ID physician, 
and cases were defined as those patients without the supervision of an ID physician. Patients who 
received OPAT from 11/2011 to 10/2012 at the infusion centers of two community teaching 
hospitals in Springfield, Illinois were retrieved from the hospitals’ electronic pharmacy 
databases. Cases were differentiated from controls by identifying the physician prescribing 
antimicrobials as either an ID specialist or not. Patients were excluded if they received fewer 
than 3 days of OPAT. We collected the following data for the cases and controls by reviewing 
individual medical records: patient demographics, infection treated, antibiotics administered, 
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physician specialty, microbiology results and monitoring.  The monitoring included frequency of 
laboratory testing, as well as serum concentration values for vancomycin and aminoglycosides. 
Two primary outcomes were assessed: adherence to monitoring of OPAT based on guidelines, 
and in patients prescribed vancomycin or an aminoglycoside, attainment of therapeutic serum 
drug concentrations.  In order to be counted as adherent to monitoring, all laboratory parameters 
would have to be ordered as recommended in table 1.  Physicians were considered non-adherent 
to monitoring if any laboratory parameter was omitted during each week of therapy. The goals 
for serum concentrations were assessed according to local hospital guidelines (Appendix A) 
based on literature and national standards.13-19 
 
Phase 2 
Based on the results of the first phase, we determined a greater need for monitoring of patients 
who did not have ID physician supervision. We hypothesized that the integration of a pharmacist 
would help improve adherence to monitoring recommendations in this patient population. 
Therefore, the second phase of the study involved implementation of pharmacy monitoring 
services for patients receiving OPAT without ID physician supervision from 11/2012 to 4/2013 
at one of the infusion centers.  
 
We chose to pilot pharmacy monitoring services of OPAT at that hospital’s infusion unit because 
of the presence of an infectious diseases pharmacy resident to assist with the program. This 
infusion center is a 24-hour ten bed facility where patients can receive blood transfusions or 
parenteral drug therapy including chemotherapy and antibiotics. The infusion center clerk sent a 
list of patients scheduled to receive that day’s medication infusions to the hospital’s central 
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pharmacy each morning. The inpatient pharmacy prepared the patients’ parenteral products as 
usual while an investigator reviewed this list for adults receiving antimicrobials prescribed by 
non-ID physicians. When eligible patients were identified, the prescribing physician was called 
to obtain approval for ordering laboratory monitoring and adjusting doses based on results. To 
create awareness of the program, hospitalist groups and case managers were educated on the 
potential service during staff meetings. Adherence to monitoring recommendations for 
outpatients under the care of a pharmacist was compared with that of historic controls, patients 
who lacked ID physician supervision before pharmacy monitoring was implemented.  
 
Analysis with Chi-square test was used to compare the categorical variables of adherence to 
monitoring recommendations and attainment of goal serum drug concentration. All tests were 2-
tailed and p<0.05 was considered statistically significant.  
 
Results 
Phase 1: Ninety nine patients receiving OPAT at the hospital infusion centers from 11/2011 to 
10/2012 were included. Of these, 39 lacked ID physician supervision. A majority of the patients 
that received OPAT were female (n=63, 64%) and the mean age was 63.1 years (SD 16.6). 
Baseline demographics between cases and controls were similar. A wide variety of clinical 
indications and microorganisms were documented (table 2). Urinary tract infections and acute 
skin or soft tissue infections were the most common diagnoses. Causative organisms were 
identified in 59 patients receiving OPAT. The most common pathogens were Staphylococcus 
aureus (20.2%) and Escherichia coli (15.1%). Table 3 lists the antimicrobials prescribed. All 
were administered intravenously. As expected, antimicrobials that can be administered once or 
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twice daily were most commonly prescribed. Vancomycin, 3rd and 4th generation cephalosporins, 
ertapenem and daptomycin were the most frequently used parenteral antimicrobials. The median 
duration of aminoglycoside therapy prescribed by both ID and non-ID physicians was 6 days. 
For vancomycin, the median duration of therapy prescribed by ID physicians was 14 days, and 
by non-ID physicians was 7 days.  
 
Patients without ID physician supervision had lower adherence to monitoring recommendations 
(35.9% vs. 68.3%; OR 3.9, 95% CI 1.6-9; p=0.003). The cases also had numerically lower 
attainment of goal vancomycin and aminoglycoside serum concentrations although this was not 
statistically significant (57.1% vs. 68.4%; OR 1.6, 95% CI 0.4-6.8; p=0.765). Table 4 lists the 
monitoring parameters that physicians (ID and non-ID) omitted. A majority of patients, whose 
physicians did not adhere to guidelines, received no additional laboratory monitoring after their 
hospital discharge.  
 
Phase 2: We piloted pharmacy monitoring services for seven patients, who received OPAT 
prescribed by non-ID physicians, at one of our infusion centers. These patients received OPAT 
for either urinary tract infection (n=4), chronic sinusitis (n=2) or osteomyelitis (n=1). 
Antibacterials administered include ceftriaxone (n=2), cefepime (n=2), and ceftazidime, 
vancomycin and gentamicin (1 each). All prescribers accepted the pharmacist’s offer to monitor 
these patients.  Adherence to monitoring recommendations for these patients was significantly 
improved compared to the patients that lacked ID physician supervision prior to pharmacy 
monitoring services being implemented (35.9% vs. 100% , p=0.0065).  
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Discussion 
To our knowledge, no reports on the consistency of OPAT monitoring have been published for 
physicians or pharmacists. We therefore assessed adherence to the laboratory monitoring 
recommendations in the IDSA guidelines for OPAT, and attainment of goal serum drug 
concentrations at two infusion centers.  
As suspected, the evaluation revealed that patients with ID physician supervision had 
significantly better adherence to monitoring recommendations. These patients had a higher 
attainment of goal serum concentrations of vancomycin and aminoglycosides as well; although, 
this was not statistically significant. Based on these results, there is room for improvement in 
both groups however with only 55.5% of the patients overall receiving monitoring consistent 
with national guidelines.  
 
In the second phase of the study, we implemented pharmacy monitoring services at one of our 
infusion centers and achieved 100% adherence to monitoring guidelines for patients on OPAT 
prescribed by non-ID physicians. It was decided to pilot these pharmacy monitoring services on 
OPAT prescribed by non-ID physicians because of lower initial adherence to monitoring 
guidelines in this group. We hypothesized that these physicians would be most amenable to 
assistance with monitoring and adjusting doses for antimicrobials.  After implementation of the 
clinical pharmacy services, attainment of goal serum drug concentrations was not compared 
since only two patients required this service. Only seven patients were enrolled in the second 
phase of the study because our study time frame was six months and the majority of OPAT at our 
institution was prescribed by ID physicians. It would have been ideal to include more patients 
over a longer time frame, but we felt this wouldn’t have changed the results. Patients that had 
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pharmacist monitoring oversight were significantly more likely to be monitored according to 
guideline recommendations after 6 months, and the pharmacists involved in preparation of the 
parenteral antimicrobials felt the process was simple enough that a sharp decline in adherence 
would be unlikely. The data was brought to the pharmacy and therapeutics committee and it was 
agreed that the practice should continue after the pharmacy resident coordinating the project left 
the medical center. This study showed that a pharmacist can follow guideline recommendations 
for monitoring OPAT and this finding is important because not all hospitals have access to ID 
physicians or require that a specialist see the patient prior to discharge on OPAT. Most infusion 
centers, however, do have pharmacists prepare the parenteral antimicrobials for outpatient 
administration; therefore, this monitoring strategy could be implemented virtually anywhere.   
The pilot program described here allowed us to test our processes and bring forth a 
recommendation that the monitoring service be continued.   
 
Our study had several limitations, however. First, we did not have access to laboratory results 
performed at outlying facilities. This could underestimate adherence to monitoring 
recommendations, but it was not expected to occur often enough to impact the results. Second, 
our sample size was limited because we were targeting only patients receiving antimicrobials at 
two infusion centers located in Springfield, Illinois, and not all locations where OPAT could be 
administered. However, we feel that the results of this study are applicable to all sites that 
provide OPAT because monitoring antibiotics is fundamental to optimizing patient care and 
preventing unnecessary adverse drug events. Third, for phase I of the study we included patients 
from two infusion centers with different hours of operation (one infusion center was operational 
for 24 hours; whereas, the other was open only from 8am-5pm). This could impact the type of 
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parenteral antimicrobial therapy received at each location. Data from two institutions had to be 
combined because OPAT has not been a common practice without ID physician supervision 
locally. Lastly, we did not participate in the diagnosis or treatment decisions for the infection, 
nor did we ascertain whether alternative parenteral or oral therapy would be more appropriate as 
other studies have evaluated.7 This data would have been helpful in providing proper 
antimicrobial stewardship.  
 
With many hospitals facing increasing economic pressures, limited space for patient care, and 
healthcare reform mandating efficient, evidence-based care, OPAT is an attractive option that 
will likely increase in popularity. With OPAT services available, stable patients can be 
discharged safely, leading to bed turnover and cost savings.3,10 It would be prudent to monitor 
these patients closely to prevent unnecessary adverse events and possible readmissions. IDSA 
proposed recommendations for monitoring patients on OPAT almost a decade ago, but little 
research in this area exists.4 Additionally, Muldoon et al suggests an OPAT bundle to enhance 
efficiency and optimize patient care.9 As part of this bundle, clinical pharmacists can play a vital 
role to improve patient care by not only supervising drug preparation, but by assessing safety and 
efficacy of pharmacotherapy through monitoring pertinent laboratory parameters, then adjusting 
and optimizing doses of antimicrobials under the supervision of a physician familiar with OPAT.  
 
A study by Heintz and colleagues looked at the impact of a multidisciplinary team review of 
OPAT prior to discharge. This team consisted of an ID physician, ID pharmacist and a case 
manager. The case manager would consult the pharmacist for further assessment of a patient 
being discharged on OPAT. The ID pharmacist, under the supervision of the ID physician, made 
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a variety of interventions focusing on safety, efficacy and simplification of complex regimens. In 
one year, these interventions led to 228 hospital days being avoided and approximately $366,000 
in hospital bed cost savings.7 Although, this would be an excellent model to follow, it is not 
feasible at all hospitals. As our results indicated, the routine monitoring of patients on OPAT 
after discharge is limited. Our study also showed the impact a pharmacist can have on adherence 
to laboratory monitoring recommendations after a patient is discharged on OPAT. This 
improvement in adherence could correlate to improved outcomes such as fewer adverse events 
and hospital readmissions. With pharmacist oversight, dosing of antimicrobials can be better 
optimized as previously documented.7 Adverse reactions could also be prevented and managed 
earlier. For example, nephrotoxicity from aminoglycosides or vancomycin can be prevented 
through vigilant monitoring and prescribing physicians can be alerted to any abnormal laboratory 
results before significant harm occurs in the patient. Therefore, pharmacists can have a 
significant role to play as part of OPAT to optimize patient care. This study serves as a 
benchmark for pharmacists, as drug therapy experts, to work in tandem with prescribers to 
manage patients on OPAT.     
 
Conclusion: 
Infectious diseases physicians are more likely to monitor patients receiving OPAT at infusion 
centers according to guidelines compared to non-ID prescribers. Attainment of goal serum drug 
concentrations was also higher in these patients, but this was not statistically significant in our 
sample. There is an opportunity for improvement in both groups, and implementing pharmacist 
oversight can improve adherence to laboratory monitoring recommendations for patients that do 
not have ID physician supervision. Future studies should evaluate whether pharmacists can 
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improve care for all OPAT patients and confirm if achievement of guideline recommendations 
provides better patient outcomes.  
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Table 1: Recommendations for laboratory monitoring of OPAT4,20,21 
Antimicrobial 
agent 
CBCa 
(no. of 
times/week) 
Renal function 
tests b 
(no. of 
times/week) 
Potassium 
level (no. of 
times/week) 
Liver 
enzyme tests 
(no. of 
times/week)  
Others 
Aminoglycosides 
(gentamicin, 
tobramycin, 
amikacin) 
Once Twice - - -Troughs as clinically indicated (if at 
steady state, can obtain q5-7 days) 
-Clinical monitoring for vestibular 
and hearing dysfunction at each visit 
Beta-lactams 
(penicillins, 
cephalosporins, 
aztreonam, 
carbapenems) 
Once Once - -c  
Antipseudomonal 
penicillins 
Once Once Once -  
Clindamycin Once Once  Once  
Daptomycin Once Once  Once CPK at least weekly 
Fluoroquinolones - - - Once  
Linezolid Once - -   
Pentamidine Twice Twice Twice Twice Blood glucose level daily; chemistry 
profile twice per week 
Quinupristin-
dalfopristin 
- - - Once Monitor for arthralgias 
Telavancind Once Once Once - Prior to use, women of childbearing 
potential should have a serum 
pregnancy test 
Tigecyclined Once - - Once  
Trimethoprim-
sulfamethoxazole 
Once Once Once -  
Vancomycin Once Once - - Troughs as clinically indicated (if at 
steady state, can obtain q5-7 days) 
Antifungals      
Amphotericin B, 
including lipid 
formulations 
Once Twice Twice Once Magnesium levels once per week 
Azole antifungals Once Once - Once  
Echinocandins 
(micafungin, 
caspofungin, 
anidulafungin) 
- - - Once  
Antivirals      
Acyclovir Once Once - - Magnesium levels once per week 
Cidofovir Once Once Once Once Urinalysis and chemistry profile 
once per week 
Foscarnet Once Twice Twice Once Chemistry profile with calcium and 
magnesium levels once per week 
Ganciclovir Twice Once - -  
 
a. CBC = Complete Blood Count,  including platelets and a differential count of leukocytes 
b. Renal function tests may include serum creatinine, blood urea nitrogen levels or urinalysis 
c. Weekly liver enzyme tests with oxacillin, nafcillin and carbapenems 
d. Telavancin and tigecycline monitoring was based on FDA-approved prescribing information  
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Table 2: Clinical and Microbiologic Indications for OPAT by Prescriber 
Non-ID Physician Patients, N=39 ID Physician Patients, N=60 
Infection n (%) Infection n (%) 
UTI 21 (46.7) SSTI 20 (32.8) 
SSTI 9 (20.0) UTI  12 (19.7) 
Bacteremia 6 (13.3) Bacteremia 8 (13.1) 
HCAP 4 (8.9) IAI 6 (9.8) 
CAP 3 (6.7) Osteomyelitis or PJI 5 (8.2) 
Osteomyelitis 1 (2.2) Endocarditis 2 (3.3) 
Chronic sinusitis 1 (2.2) HCAP 2 (3.3) 
  PJI 2 (3.3) 
  Chronic sinusitis 2 (3.3) 
  Meningitis 1 (1.6) 
  Syphilis 1 (1.6) 
    
Microbiology 
results 
n (%) Microbiology 
results 
n (%) 
Culture negative 14 (29.8) Culture negative 26 (36.6) 
Escherichia coli 9 (19.1) MRSA 10 (14.1) 
Pseudomonas 
aeruginosa 6 (12.8) Escherichia coli 6 (8.5) 
Klebsiella pneumoniae 5 (10.6) MSSA 5 (7.0) 
MRSA 4 (8.5) Anaerobes* 5 (7.0) 
Enterobacter cloacae 2 (4.3) 
Coagulase negative 
Staphylococcus spp. 3 (4.2) 
Viridans Streptococcus 1 (2.1) Viridans Streptococcus 3 (4.2) 
Streptococcus 
pneumoniae 1 (2.1) 
Microaerophilic 
Streptococcus  2 (2.8) 
Serratia marcescens 1 (2.1) Proteus mirabilis 2 (2.8) 
MSSA 1 (2.1) Pseudomonas aeruginosa 2 (2.8) 
Morganella morganii 1 (2.1) Streptococcus pneumoniae 1 (1.4) 
Klebsiella oxytoca 1 (2.1) Citrobacter koseri 1 (1.4) 
Group B Streptococcus 1 (2.1) Morganella morganii 1 (1.4) 
  Aerococcus urinae 1 (1.4) 
  Citrobacter freundii 1 (1.4) 
  Enterococcus faecalis 1 (1.4) 
  Klebsiella pneumoniae 1 (1.4) 
Note: Values add up to greater than 100% because some patients had more than one infection 
Key: MRSA: methicillin resistant Staphylococcus aureus; MSSA: methicillin susceptible 
Staphylococcus aureus; SSTI: skin or tissue infections; UTI: urinary tract infections; HCAP: 
health-care associated pneumonia; CAP: community acquired pneumonia; IAI: intra-abdominal 
infections; PJI: prosthetic joint infections; *Anaerobes: Peptostreptococcus spp. (n=2), 
Bacteroides fragilis (n=1), Clostridium spp.,non-difficile (n=1), Prevotella spp. (n=1) 
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Table 3: Antibacterials administered based on physician supervision 
 
Non-ID physician ID physician  
Drug n (%) Drug n (%) 
Ceftriaxone 11 (25.6) Vancomycin 13 (19.7) 
Cefepime 8 (18.6) Daptomycin 12 (18.2) 
Gentamicin 7 (16.3) Ertapenem 11 (16.7) 
Ertapenem 5 (11.6) Ceftriaxone 8 (12.1) 
Vancomycin 5 (11.6) Cefepime 7 (10.6) 
Tobramycin 2 (4.7) Gentamicin 7 (10.6) 
Daptomycin 2 (4.7) Tobramycin 3 (4.5) 
Linezolid 1 (2.3) Benzathine Penicillin G 1 (1.5) 
Azithromycin 1 (2.3) Ceftazidime 1 (1.5) 
Meropenem 1 (2.3) Tigecycline 1 (1.5) 
  Linezolid 1 (1.5) 
  Azithromycin 1 (1.5) 
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Table 4: Weekly laboratory parameters not ordered as recommended by guidelines 
 
Non ID physicians 
Antimicrobial 
agent (N) 
Complete blood 
count (n) 
Renal function 
tests (n) 
Liver enzyme 
tests (n) 
CPK (n) 
Ceftriaxone (11) 5 (45%) 5 (45%) 7 (64%) - 
Gentamicin (7) 6 (86%) 4 (57%) - - 
Tobramycin (2) 1 (50%) 1 (50%) - - 
Ertapenem (5) 1 (20%) 1 (20%) 2 (40%) - 
Cefepime (8) 4 (50%) 4 (50%) - - 
Daptomycin (2) - - - 2 (100%) 
Vancomycin (5) 2 (40%) 1 (20%) - - 
Meropenem (1) 1 (100%) 1 (100%) 1 (100%) - 
 
ID physicians 
Antimicrobial 
agent (N) 
Complete blood 
count (n) 
Renal function 
tests (n) 
Liver enzyme 
tests (n) 
CPK (n) 
Ceftriaxone (8) 4 (50%) 4 (50%) 4 (50%) - 
Tobramycin (3) 1 (33%) 1 (33%) - - 
Ertapenem (11) - - 2 (18%) - 
Daptomycin (12) 3 (25%) 3 (25%) 3 (25%) 6 (50%) 
Vancomycin (13) 5 (38%) 5 (38%) - - 
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Appendix A: Goals for Serum Drug Concentrations 
 
1. Vancomycin13,14   
a. Severe infections (e.g. meningitis, pneumonia, endocarditis, bacteremia, severe soft 
tissue infection or osteomyelitis): trough between 15-20 mcg/mL  
b. Mild to moderate skin and soft tissue or urinary tract infection (after ruling out 
systemic disease): trough between 10-15 mcg/mL 
 
2. Aminoglycosides – conventional dosing15,16 
a. Peak: 
i. Severe infections (e.g. bacteremia, neutropenic fever, pneumonia):  
a. Gentamicin and tobramycin: 8-12 mcg/mL 
b. Amikacin: 25-40 mcg/mL 
ii. Mild to moderate infections (e.g. pyelonephritis, urinary tract infections):  
a. Gentamicin and tobramycin: 5-8 mcg/mL 
b. Amikacin: 15-25 mcg/mL 
iii. Synergy (gentamicin only) for gram positive organisms: 3-5 mcg/mL 
b. Trough (gentamicin and tobramycin): 
i. Severe infections:  
a. Gentamicin and tobramycin: <2mcg/mL 
b. Amikacin: <10mcg/mL 
ii. Mild to moderate infections and synergy (gentamicin only) for gram positive 
organisms:  
a. Gentamicin and tobramycin: <1mcg/mL  
b. Amikacin: <10mcg/mL 
 
3. Aminoglycosides – once-daily dosing16-19 
a. Trough (gentamicin, tobramycin and amikacin): <1mcg/mL 
b. 16-18 hours post-infusion serum aminoglycoside concentration:17,18  
i. Gentamicin and tobramycin: < 2 mcg/mL 
ii. Amikacin: 2.5 – 5 mcg/mL 
c. 6-14 hours post-infusion serum aminoglycoside concentration 
i. Follow nomogram, as suggested by Nicolau et al19 
  
 
 
 
